LeMaitre Vascular, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5255582018
USD
85.70
2.02 (2.41%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About LeMaitre Vascular, Inc. stock-summary
stock-summary
LeMaitre Vascular, Inc.
Pharmaceuticals & Biotechnology
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company's product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
Company Coordinates stock-summary
Company Details
63 2nd Ave , BURLINGTON MA : 01803-4413
stock-summary
Tel: 1 781 2212266
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 81 Schemes (46.54%)

Foreign Institutions

Held by 99 Foreign Institutions (5.54%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. George LeMaitre
Chairman of the Board, Chief Executive Officer
Mr. David Roberts
President, Director
Mr. Joseph Pellegrino
Chief Financial Officer, Director
Mr. Lawrence Jasinski
Independent Director
Mr. John O'Connor
Independent Director
Ms. Bridget Ross
Independent Director
Mr. John Roush
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
64 Million
(Quarterly Results - Jun 2025)
Net Profit:
14 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,347 Million (Small Cap)

stock-summary
P/E

45.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

72.08%

stock-summary
Debt Equity

-0.41

stock-summary
Return on Equity

13.00%

stock-summary
Price to Book

6.47